Get the Stockscreener App
48.57
0.16%
0.08
After Hours:
48.57
Royalty Pharma Plc stock is traded at $48.57, with a volume of 2.71M.
It is up +0.16% in the last 24 hours and up +2.32% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$48.49
Open:
$48.25
24h Volume:
2.71M
Relative Volume:
0.75
Market Cap:
$20.81B
Revenue:
$2.38B
Net Income/Loss:
$1.32B
P/E Ratio:
27.28
EPS:
1.7806
Net Cash Flow:
$897.24M
1W Performance:
+3.47%
1M Performance:
+2.32%
6M Performance:
+33.10%
1Y Performance:
+55.27%
1-Day Range:
$48.21
$49.06
1-Week Range:
$46.06
$49.06
52-Week Range:
$29.66
$49.06
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
48.57 | 20.77B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal - Yahoo Finance UK
Multiple RPRX Share Disposals by TPC RP Entities (RPRX) - Stock Titan
Pablo Legorreta: Pioneer of Pharmaceutical Royalties, Financial Innovator, and Founder and CEO of Royalty Pharma - BBN Times
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - The Manila Times
J. Safra Sarasin Holding AG Purchases Shares of 90,035 Royalty Pharma PLC $RPRX - MarketBeat
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Royalty Pharma stock hits 52-week high at $47.87 By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (RPRX) director granted 815-share equity award - Stock Titan
Royalty Pharma stock hits 52-week high at $47.87 - Investing.com
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
TD Cowen reiterates Royalty Pharma stock Buy rating on lupus drug potential By Investing.com - Investing.com South Africa
Royalty Pharma and J&J partner to develop autoimmune treatment - Yahoo Finance
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Royalty Pharma in $500M R&D funding collaboration with J&J - MSN
Royalty Pharma commits $500M to J&J autoimmune drug development By Investing.com - Investing.com India
Royalty Pharma commits $500M to J&J autoimmune drug development - Investing.com
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases - Bitget
Johnson & Johnson taps Royalty Pharma for $500M autoimmune drug push - Stock Titan
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Refreshes Leadership As AI And Asia Shape Valuation Story - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment - ChartMill
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - MSN
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com - Investing.com Australia
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $1.58 million - Investing.com
Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan - Stock Titan
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Nordea Investment Management AB Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy - Sahm
Royalty Pharma names Lucas Glass as head of artificial intelligence By Investing.com - Investing.com India
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance UK
Affiliates of RPRX sell multiple blocks of common stock (RPRX) - Stock Titan
Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026 - MarketScreener
Royalty Pharma names Lucas Glass as head of artificial intelligence - Investing.com
Royalty Pharma plc (RPRX) Latest Stock News & Headlines - Yahoo Finance
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence - The Globe and Mail
How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations - Yahoo Finance
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
(RPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FOMO Trade: Will Royalty Pharma plc benefit from rate cuts2026 Setups & AI Optimized Trade Strategies - baoquankhu1.vn
Royalty Pharma PLC $RPRX Shares Purchased by Tudor Investment Corp ET AL - MarketBeat
S&P 500 Futures Decline In Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Moomoo
S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Barron's
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Mar 23 '26 |
Sale |
45.53 |
34,791 |
1,583,989 |
43,886 |
1.76%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):